📗 Cite This Artifact
📖
Tau PET Imaging
active
wiki page
Created: 2026-04-02T07:20:09
By: crosslink-migration
Quality:
50%
✓ SciDEX
ID: wiki-diagnostics-tau-pet-imaging
📖 Wiki Page
diagnostic2495 wordssynced 2026-04-02
Introduction
Overview
[Tau](/proteins/tau) Positron Emission Tomography (PET) imaging is a molecular imaging technique that allows visualization and quantification of [tau protein](/proteins/tau) pathology in the living brain[@okamura2005]. [tau protein](/proteins/tau), which forms neurofibrillary tangles (NFTs), is one of the hallmark pathological features of [Alzheimer's Disease](/diseases/alzheimers-disease) and several other neurodegenerative disorders. Tau PET imaging has revolutionized our ability to track disease progression, assess therapeutic efficacy, and understand the relationship between tau pathology and clinical symptoms[@zhang2012]. [@okamura2005]
History and Development
The development of tau PET tracers began after successful amyloid PET tracers like Pittsburgh Compound-B (PiB) demonstrated the feasibility of imaging [Amyloid-Beta](/proteins/amyloid-beta) plaques. The first generation of tau PET tracers included: [@zhang2012]
- Flortaucipir (F-18 AV-1451, Tauvid): Developed by Avid Radiopharmaceuticals, this was the first FDA-approved tau PET tracer for imaging tau pathology in AD[@chien2013]
- THK5317 and THK5351: Developed by Tohoku University
- PBB3: Developed by Cyclotron in Japan
Mechanism of Tau PET Tracers
Binding Characteristics
Tau PET tracers bind to: [@chien2013]
Tracer Kinetics
...
Introduction
Overview
[Tau](/proteins/tau) Positron Emission Tomography (PET) imaging is a molecular imaging technique that allows visualization and quantification of [tau protein](/proteins/tau) pathology in the living brain[@okamura2005]. [tau protein](/proteins/tau), which forms neurofibrillary tangles (NFTs), is one of the hallmark pathological features of [Alzheimer's Disease](/diseases/alzheimers-disease) and several other neurodegenerative disorders. Tau PET imaging has revolutionized our ability to track disease progression, assess therapeutic efficacy, and understand the relationship between tau pathology and clinical symptoms[@zhang2012]. [@okamura2005]
History and Development
The development of tau PET tracers began after successful amyloid PET tracers like Pittsburgh Compound-B (PiB) demonstrated the feasibility of imaging [Amyloid-Beta](/proteins/amyloid-beta) plaques. The first generation of tau PET tracers included: [@zhang2012]
- Flortaucipir (F-18 AV-1451, Tauvid): Developed by Avid Radiopharmaceuticals, this was the first FDA-approved tau PET tracer for imaging tau pathology in AD[@chien2013]
- THK5317 and THK5351: Developed by Tohoku University
- PBB3: Developed by Cyclotron in Japan
Mechanism of Tau PET Tracers
Binding Characteristics
Tau PET tracers bind to: [@chien2013]
Tracer Kinetics
Ideal tau PET tracers should have: [@johnson2016]
- High brain uptake
- Low non-specific binding
- Fast washout from non-target regions
- Appropriate binding kinetics
Clinical Applications
Diagnosis and Differential Diagnosis
Tau PET helps distinguish between:
- Alzheimer's Disease vs. other dementias
- Alzheimer's Disease vs. primary tauopathies[@brier2016]
Disease Staging
Tau PET follows the Braak staging of tau pathology:
- Stage I-II: Limbic region involvement
- Stage III-IV: Isocortical involvement
- Stage V-VI: Widespread cortical involvement[@scholl2016]
Treatment Monitoring
Tau PET is essential for:
- Anti-tau therapy trials
- Dose-finding studies
- Patient stratification[@ossenkoppele2015]
Regional Patterns of Tau Deposition
Alzheimer's Disease
In AD, tau deposition follows a characteristic pattern:
- Entorhinal [cortex](/brain-regions/cortex): Early involvement
- [Hippocampus](/brain-regions/hippocampus): Limbic stage
- Posterior cingulate: Transitional
- Prefrontal cortex: Late stage[@gordon2018]
Primary Tauopathies
Different tracers show varying binding to:
CBS and PSP Tau PET Patterns
Tau PET imaging using tracers like [^18F]flortaucipir (FTP) shows distinct patterns in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) that help differentiate these 4R tauopathies from Alzheimer's disease.
CBS Patterns
In corticobasal syndrome, tau PET shows:
- Asymmetric uptake: Often more pronounced in one hemisphere, corresponding to the more affected side clinically
- Cortical involvement: Parietal, posterior temporal, and occipital regions are typically affected
- Motor cortex: Primary motor and premotor cortex show uptake
- Subcortical structures: Putamen and caudate may show binding
- Pattern distinction: Generally less entorhinal/hippocampal uptake compared to AD
PSP Patterns
In progressive supranuclear palsy, tau PET shows:
- Brainstem predominance: Midbrain, pons, and substantia nigra show characteristic uptake
- Globus pallidus: Strong uptake in the globus pallidus internus
- Subthalamic nucleus: Variable uptake in the STN
- Cortical sparing: Generally less cortical uptake than AD
- Midbrain atrophy: Often visible on structural MRI alongside tau PET findings
Differential Diagnosis: CBS/PSP vs. AD
| Feature | CBS | PSP | AD |
|---------|-----|-----|-----|
| Temporal lobe | Moderate | Low | High |
| Parietal/occipital | High | Low | High |
| Brainstem | Moderate | High | Low |
| Basal ganglia | High | High | Low |
| Asymmetry | Strong | Mild | None |
Clinical Utility
Tau PET in CBS/PSP is used for:
Tau Tracer Development
First-Generation Tracers
The initial tau PET tracers were developed based on amyloid imaging principles:
[^18F]Flortaucipir (AV-1451, Tauvid)
- FDA approved in 2020 for tau imaging[@fda2020]
- High affinity for AD-type tau (3R/4R)[@xia2013]
- Excellent signal-to-background ratio[@lowe2016]
- Limitations: Off-target binding in basal ganglia[@hansen2016]
- Second-generation tracer with broader specificity[@maruyama2013]
- Binds to both AD and non-AD tauopathies[@pereznievas2013]
- Allows visualization of 4R-tauopathies[@shimada2015]
- Limited availability due to [^11C] half-life[@hashimoto2015]
Second-Generation Tracers
[^18F]MK-6240
- High affinity for AD tau[@swaminathan2018]
- Reduced off-target binding[@hostetler2018]
- Excellent kinetic properties[@sur2019]
- High specificity for AD tau pathology[@walji2016]
- Minimal off-target binding[@mueller2017]
- Good test-retest reliability[@brendel2020]
- Binds to 3R/4R and 4R tauopathies[@song2019]
- Suitable for PSP, CBD imaging[@hammes2019]
- Currently in clinical development[@beyer2020]
Imaging Biomarkers
Tau Deposition Patterns
Regional tau PET signal follows the characteristic Braak staging progression:
| Stage | Brain Regions | Clinical Correlation |
|-------|---------------|---------------------|
| I-II | Transentorhinal | Preclinical |
| III-IV | Limbic | MCI/early AD |
| V-VI | Isocortical | Moderate-severe AD |
Quantification Methods
| Metric | Description | Clinical Use |
|--------|-------------|--------------|
| SUVR | Standardized uptake value ratio | Regional burden |
| Centiloid-T | Tau-specific centiloid scale | Cross-study comparison |
| Braak ROI | Region-specific staging | Disease staging |
| DVR | Distribution volume ratio | Kinetic modeling |
Clinical Applications
Alzheimer's Disease Diagnosis
Diagnostic Utility
- Sensitivity: 85-95% for detecting tau pathology[@fleisher2021]
- Specificity: 90-95% for AD vs. other tauopathies[@ossenkoppele2021]
- Earlier detection than clinical symptoms[@sperling2011]
- Distinguishes AD from FTD spectrum[@rascovsky2011]
- Helps identify AD vs. DLB[@gomperts2016]
- Differentiates AD from PSP/CBS[@passamonti2017]
Disease Staging
Braak Staging In Vivo
- Tau PET tracks NFT progression[@braak2006]
- Correlates with neuropathological staging[@scholl2016a]
- Enables early intervention planning[@harrison2021]
- Global tau burden correlates with cognitive impairment[@brier2016a]
- Regional patterns predict specific deficits[@la2019]
- Helps predict rate of progression[@koychev2017]
Prognostic Applications
Cognitive Decline Prediction
- Baseline tau PET predicts future cognitive loss[@jack2018]
- Rate of tau accumulation forecasts decline[@betthauser2020a]
- Combined with amyloid improves prediction[@hansson2020]
Technical Considerations
Image Acquisition
Scanning Protocol
- Injection dose: 185-370 MBq (5-10 mCi)[@schmidt2015]
- Acquisition: 80-120 minutes post-injection[@shcherbakova2019]
- Reconstruction: Standard filtered back-projection or OSEM[@rahmim2008]
- Motion correction essential[@zhou2021]
- Attenuation correction accuracy[@burger2009]
- Standardized preprocessing pipeline[@landau2015]
Quantification Standardization
Cross-Sectional Measures
- Regional SUVr with cerebellar reference[@maass2017]
- Composite tau burden scores[@baker2017]
- Centiloid-T transformation[@whittington2018]
- Annualized rate of change[@chen2018]
- Voxel-wise statistical maps[@zhou2019]
- Region of interest analysis[@lee2019]
Comparison with Other Biomarkers
Tau CSF vs. PET
| Feature | CSF p-tau | Tau PET |
|---------|-----------|---------|
| Specificity | High | Very high |
| Spatial resolution | Global only | Regional |
| Disease staging | Limited | Excellent |
| Accessibility | Good | Limited |
Amyloid-Tau Interaction
- Amyloid positivity enables tau spread[@hardiman2016]
- Tau PET signal absent in amyloid-negative individuals[@rowe2010]
- Combined amyloid-tau imaging optimal for diagnosis[@hampton2021]
Clinical Trial Applications
Patient Selection
- Tau PET identifies AD with high certainty[@cummings2023]
- Enriches trials for tau-positive patients[@aisen2021]
- Stratifies by disease stage[@mcdade2023]
Pharmacodynamic Markers
- Tau PET tracks treatment effects[@mintun2021]
- Anti-tau therapy monitoring[@hyman2021]
- Dose-response relationships[@sevigny2016]
Surrogate Endpoints
- Tau accumulation as trial endpoint[@ramsden2005]
- Accelerated approval pathways[@fda2023]
- Disease modification evidence[@aisen2022]
Disease-Specific Patterns
Alzheimer's Disease
- [Entorhinal cortex](/brain-regions/entorhinal-cortex) → hippocampus → inferior temporal[@la2019a]
- Precuneus and posterior cingulate[@brier2016b]
- Spreads to frontal regions in advanced disease[@farrell2018]
Progressive Supranuclear Palsy
- Midbrain, globus pallidus, dentate nucleus[@shoji2015]
- Relative sparing of neocortex[@passamonti2017a]
- Distinct from AD pattern[@whitwell2013]
Corticobasal Degeneration
- Motor cortex, premotor, superior frontal[@alexander2016]
- Asymmetric often observed[@boeve2013]
- Different from PSP pattern[@lee2017]
Chronic Traumatic Encephalopathy
- Cortical and white matter binding[@stern2019]
- Distinct from AD distribution[@alosco2018]
- Currently research use[@mckee2020]
Limitations
Technical Limitations
- Off-target binding in certain brain regions[@lemoine2017]
- Partial volume effects[@su2013]
- Limited availability of tracers[@boellaard2015]
Clinical Limitations
- Cannot detect early tau changes[@cho2015]
- Floor effect in advanced disease[@villemagne2013]
- Cannot distinguish tau species[@goedert2019]
Practical Limitations
- High cost of scanning[@cms2023]
- Radiation exposure[@icrp2007]
- Access disparities[@oecd2023]
Future Directions
Tracer Development
- Improved specificity for non-AD tauopathies[@leuzy2020]
- Agents for tau oligomers[@masliah2016]
- Theranostic applications[@veerappan2012]
Quantification Advances
- Machine learning pattern recognition[@lee2019a]
- Automated interpretation tools[@zhang2021]
- Standardized reporting[@marinescu2020]
Clinical Integration
- Blood-based tau as screening[@janelidze2020]
- Combined amyloid-tau-PET protocols[@zetterberg2021]
- Point-of-care imaging[@kaye2021]
References
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Related Entities
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | diagnostics-tau-pet-imaging |
| kg_node_id | None |
| entity_type | diagnostic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-f420cbf689a7 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'diagnostics-tau-pet-imaging'} |
| _schema_version | 1 |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
28
Outgoing
28
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
1 nodes, 0 edges
No provenance edges found
This artifact has no version history yet.
Linked Artifacts (56)
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/wiki-diagnostics-tau-pet-imaging?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Tau PET Imaging](http://scidex.ai/artifact/wiki-diagnostics-tau-pet-imaging)
Direct URL
http://scidex.ai/artifact/wiki-diagnostics-tau-pet-imaging
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.